Neogenomics Inc
NEO- Exchange
- Nasdaq
- Industry
- Services-Testing Laboratories
- SEC CIK
- 0001077183
No open-market purchases or sales by Neogenomics Inc insiders were filed in the last 90 days; 266 institutions reported holding it in 13F filings for Q2 2026, worth $2.11B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 29, 2026, 1:13 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $108.0M (14.9% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 18, 2025 | Feb 20, 2024 | Feb 23, 2023 | Feb 23, 2022 |
| Revenue | $727.3M | $660.6M | $591.6M | $509.7M | $484.3M |
| Cost of revenue | $413.0M | $370.5M | $347.0M | $321.8M | $297.3M |
| Gross profit | $314.3M | $290.1M | $244.6M | $187.9M | $187.1M |
| Operating expenses | $430.2M | $382.2M | $352.3M | $345.5M | $305.8M |
| Research and development | $37.1M | $31.2M | $27.3M | $30.3M | $21.9M |
| Selling, general and administrative | $273.3M | $259.7M | $243.1M | $243.4M | $221.3M |
| Operating income | -$115.9M | -$92.1M | -$107.7M | -$157.6M | -$118.8M |
| Interest expense | – | – | $6.91M | $1.51M | $5.08M |
| Income tax | -$2.24M | -$1.95M | -$9.13M | -$15.1M | -$6.73M |
| Net income | -$108.0M | -$78.7M | -$88.0M | -$144.3M | -$8.35M |
| Weighted shares, basic | 128.1M | 126.7M | 125.5M | 124.2M | 120.0M |
| Weighted shares, diluted | 128.1M | 126.7M | 125.5M | 124.2M | 120.0M |
| Margins and growth | |||||
| Gross margin | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% |
| Operating margin | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% |
| Net margin | -14.9% | -11.9% | -14.9% | -28.3% | -1.7% |
| Revenue growth, year over year | +10.1% | +11.6% | +16.1% | +5.2% | +9.0% |
| Net income growth, year over year | – | – | – | – | −300.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 18, 2025 | Feb 20, 2024 | Feb 23, 2023 | Feb 23, 2022 |
| Cash and equivalents | $159.6M | $367.0M | $342.5M | $263.2M | $316.8M |
| Accounts receivable | $159.2M | $150.5M | $131.2M | $119.7M | $112.1M |
| Inventory | $28.6M | $26.7M | $24.2M | $24.3M | $23.4M |
| Total current assets | $376.3M | $596.0M | $596.8M | $605.3M | $681.5M |
| Property, plant and equipment | $84.8M | $94.1M | $92.0M | $102.5M | $109.5M |
| Goodwill | $524.3M | $522.8M | $522.8M | $522.8M | $527.1M |
| Intangible assets | $286.5M | $339.7M | $373.1M | $408.3M | $442.3M |
| Total assets | $1.36B | $1.64B | $1.68B | $1.74B | $1.87B |
| Accounts payable | $23.1M | $21.6M | $20.3M | $20.5M | $17.9M |
| Short-term debt | $0 | $200.8M | – | – | – |
| Total current liabilities | $88.3M | $301.2M | $96.3M | $89.9M | $87.2M |
| Long-term debt | $341.9M | $340.3M | – | – | – |
| Total liabilities | $523.3M | $735.7M | $739.7M | $742.0M | $761.5M |
| Shareholders' equity | $836.6M | $902.3M | $941.5M | $998.0M | $1.11B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 18, 2025 | Feb 20, 2024 | Feb 23, 2023 | Feb 23, 2022 |
| Operating cash flow | $5.23M | $7.02M | -$1.95M | -$66.0M | -$26.7M |
| Capital expenditures | $27.0M | $41.1M | $28.8M | $30.9M | $64.1M |
| Free cash flow | -$21.8M | -$34.0M | -$30.7M | -$96.9M | -$90.9M |
| Stock-based compensation | $41.3M | $33.4M | $24.6M | $24.7M | $22.5M |
| Investing cash flow | -$12.3M | $12.9M | $76.7M | $517.0K | -$632.4M |
| Financing cash flow | -$200.3M | $4.65M | $4.55M | $11.8M | $725.3M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 5.7% | 5.1% | 4.2% | 4.8% | 4.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 23, 2026 | 129.4M | 0.0% | SEC |
| Jul 24, 2026 | 128.5M | −0.5% | SEC |
| Apr 24, 2026 | 130.2M | +1.2% | SEC |
| Feb 13, 2026 | 129.8M | +1.1% | SEC |
| Oct 24, 2025 | 129.4M | +0.8% | SEC |
| Jul 25, 2025 | 129.2M | +0.8% | SEC |
| Apr 25, 2025 | 128.7M | +0.8% | SEC |
| Feb 11, 2025 | 128.5M | +0.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.